ArticleEuropean journal of microbiology & immunology2026
Head-to-head evaluation of a commercial real-time PCR assay targeting plasmodial species causing human malaria against a composite reference standard.
Article in European journal of microbiology & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The investigation was conducted to evaluate a robust commercial multiplexed species- or species complex-specific real-time PCR assay for human malaria applicable with mobile cyclers. Methods: A well-characterized sample set of blood samples from travelers with high pre-test probability of being infected with plasmodial species was assessed with the Plasmodium qPCR panel (Bioeksen, Istanbul, Turkey) against a composite reference standard comprising microscopy following the protocols by World Health Organization in combination with four nucleic acid amplification tests for malaria. Results: From 1,020 included samples, composite reference standard testing identified 248 (24.3%) as positive for plasmodial DNA, comprising 217x Plasmodium falciparum, 14x Plasmodium vivax, 8x Plasmodium ovale complex, 6x Plasmodium malariae and 3 samples containing DNA of both P. falciparum and P. vivax. Diagnostic accuracy of the evaluated PCR in terms of sensitivity and specificity was 96.8% (240/248) and 99.5% (768/772). The resulting positive and negative predictive values were 98.4% (240/244) and 99.0% (768/776). False-negative results were associated with either submicroscopic parasitemia or parasitemia at the threshold of microscopic detection. Conclusion: The assessed multiplex real-time PCR assay showed similar performance characteristics like comparable diagnostic assays and thus proved to be suitable for the differentiation of plasmodia in the non-endemic setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.